{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:24:31Z","timestamp":1791559471269,"version":"4.3.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-026-01175-6","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:41:53Z","timestamp":1788327713000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biopsy-proven kidney-limited thrombotic microangiopathy associated with bevacizumab and pegylated liposomal doxorubicin: a case with a biphasic clinical course"],"prefix":"10.1007","volume":"15","author":[{"given":"Naoki","family":"Chigusa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4809-5788","authenticated-orcid":false,"given":"Tatsuhiko","family":"Azegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashin","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Hishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aika","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Hashiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"1175_CR1","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1053\/j.ajkd.2022.10.014","volume":"81","author":"DS Genest","year":"2023","unstructured":"Genest DS, Patriquin CJ, Licht C, John R, Reich HN. Renal thrombotic microangiopathy: a review. Am J Kidney Dis. 2023;81:591\u2013605.","journal-title":"Am J Kidney Dis"},{"key":"1175_CR2","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371:654\u201366.","journal-title":"N Engl J Med"},{"key":"1175_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MD.0000000000000207","volume":"93","author":"H Izzedine","year":"2014","unstructured":"Izzedine H, Escudier B, Lhomme C, Pautier P, Rouvier P, Gueutin V, et al. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine. 2014;93:333\u20139.","journal-title":"Medicine"},{"key":"1175_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/ki.2013.408","volume":"85","author":"L Shavit","year":"2014","unstructured":"Shavit L, Lifschitz MD, Gabizon A, Kwa M, Muggia F, Slotki I. Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer. Kidney Int. 2014;85:213.","journal-title":"Kidney Int"},{"key":"1175_CR5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41379-018-0186-4","volume":"32","author":"F Person","year":"2019","unstructured":"Person F, Rinschen MM, Brix SR, Wulf S, Noriega MLM, Fehrle W, et al. Bevacizumab-associated glomerular microangiopathy. Mod Pathol. 2019;32:684\u2013700.","journal-title":"Mod Pathol"},{"key":"1175_CR6","doi-asserted-by":"publisher","first-page":"E369","DOI":"10.1002\/ajh.27101","volume":"98","author":"N Klomjit","year":"2023","unstructured":"Klomjit N, Evans R, Le TK, Wells SL, Ortega J, Green-Lingren O, et al. Frequency and characteristics of chemotherapy-associated thrombotic microangiopathy: analysis from a large pharmacovigilance database. Am J Hematol. 2023;98:E369\u201372.","journal-title":"Am J Hematol"},{"key":"1175_CR7","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1634\/theoncologist.2011-0422","volume":"17","author":"M Kwa","year":"2012","unstructured":"Kwa M, Baumgartner R, Shavit L, Barash I, Michael J, Puzanov I, et al. Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences? Oncologist. 2012;17:1534\u201340.","journal-title":"Oncologist"},{"key":"1175_CR8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","volume":"66","author":"H Izzedine","year":"2015","unstructured":"Izzedine H, Perazella MA. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis. 2015;66:857\u201368.","journal-title":"Am J Kidney Dis"},{"key":"1175_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00280-020-04203-z","volume":"87","author":"M Savani","year":"2021","unstructured":"Savani M, Woerner K, Bu L, Birkenbach M, Skubitz KM. Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review. Cancer Chemother Pharmacol. 2021;87:289\u201394.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1175_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2022.100461","volume":"4","author":"S Rodriguez-Ramirez","year":"2022","unstructured":"Rodriguez-Ramirez S, Yau K, Kitchlu A, John R, Rose AAN, Hogg D, et al. Pegylated liposomal doxorubicin and kidney-limited thrombotic microangiopathy in a kidney transplant recipient: a case report. Kidney Med. 2022;4:100461.","journal-title":"Kidney Med"},{"key":"1175_CR11","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.2169\/internalmedicine.3113-23","volume":"63","author":"S Yokoyama","year":"2024","unstructured":"Yokoyama S, Kakeshita K, Imamura T, Shima T, Fujioka H, Yamazaki H, et al. Pegylated-liposomal doxorubicin-induced glomerular thrombotic microangiopathy. Intern Med. 2024;63:2839\u201345.","journal-title":"Intern Med"},{"key":"1175_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1053\/j.ajkd.2023.08.014","volume":"83","author":"I Glezerman","year":"2024","unstructured":"Glezerman I, Salvatore S, Tap W, Kelly C, Brauer Ornelas CM, Shaikh A. Pegylated liposomal doxorubicin causes kidney-limited thrombotic microangiopathy. Am J Kidney Dis. 2024;83:549\u201353.","journal-title":"Am J Kidney Dis"},{"key":"1175_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2025.100998","volume":"7","author":"TS Karam","year":"2025","unstructured":"Karam TS, Sarkar M, Zuckerman JE. Acute kidney injury secondary to pegylated liposomal doxorubicin-associated renal-limited thrombotic microangiopathy. Kidney Med. 2025;7:100998.","journal-title":"Kidney Med"},{"key":"1175_CR14","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1053\/j.ajkd.2012.08.048","volume":"61","author":"N Mohamed","year":"2013","unstructured":"Mohamed N, Goldstein J, Schiff J, John R. Collapsing glomerulopathy following anthracycline therapy. Am J Kidney Dis. 2013;61:778\u201381.","journal-title":"Am J Kidney Dis"},{"key":"1175_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","volume":"42","author":"A Gabizon","year":"2003","unstructured":"Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42:419\u201336.","journal-title":"Clin Pharmacokinet"},{"key":"1175_CR16","first-page":"987","volume":"54","author":"A Gabizon","year":"1994","unstructured":"Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54:987\u201392.","journal-title":"Cancer Res"},{"key":"1175_CR17","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1080\/14686996.2019.1627174","volume":"20","author":"M Mohamed","year":"2019","unstructured":"Mohamed M, Abu Lila AS, Shimizu T, Alaaeldin E, Hussein A, Sarhan HA, et al. PEGylated liposomes: immunological responses. Sci Technol Adv Mater. 2019;20:710\u201324.","journal-title":"Sci Technol Adv Mater"},{"key":"1175_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","volume":"46","author":"H Izzedine","year":"2010","unstructured":"Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer. 2010;46:439\u201348.","journal-title":"Eur J Cancer"},{"key":"1175_CR19","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/his.13716","volume":"73","author":"F Pfister","year":"2018","unstructured":"Pfister F, Amann K, Daniel C, Klewer M, B\u00fcttner A, B\u00fcttner-Herold M. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy. Histopathology. 2018;73:990\u20131001.","journal-title":"Histopathology"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-026-01175-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-026-01175-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-026-01175-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:41:55Z","timestamp":1788327715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-026-01175-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["1175"],"URL":"https:\/\/doi.org\/10.1007\/s13730-026-01175-6","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"10 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Takashi Nakayama is an employee of Boehringer Ingelheim Japan Inc., which was not involved in this case report. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the Declaration of Helsinki guidelines.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed and written signed consent was provided by the patient.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"139"}}